Form 4: Teladoc Health Executive Sells Shares for Tax Obligations

Teladoc Health's President of U.S. Group Health, Kelly Bliss, sold 4,700 shares of common stock to cover tax withholdings following the vesting of equity awards.

Summary

• Kelly Bliss, President, U.S. Group Health at Teladoc Health, Inc. (TDOC), reported transactions involving company common stock.
• On August 29, 2025, Bliss acquired a total of 9,535 shares of common stock through the conversion of 1,189 performance stock units and 8,346 restricted stock units.
• Following these acquisitions, Bliss's direct beneficial ownership increased to 59,801 shares.
• On September 2, 2025, Bliss sold 4,700 shares of common stock at a price of $7.585 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting of the equity awards.
• After the sale, Bliss's direct beneficial ownership of common stock was 55,101 shares.

Sentiment

Score: 5

Explanation: The transactions are routine for executive compensation and tax management, involving both acquisition of shares through vesting and a subsequent sale to cover tax obligations. This does not indicate a significant positive or negative shift in company fundamentals or executive confidence.

Positives

• The vesting of performance stock units and restricted stock units indicates the achievement of performance targets or continued employment, reflecting positively on executive retention and potential company performance.
• The conversion of 9,535 derivative securities into common stock demonstrates the executive's continued participation in the company's equity.

Negatives

• The sale of 4,700 shares, even for tax purposes, reduces the executive's direct ownership stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market risk associated with holding equity.

Future Outlook

The filing indicates future vesting schedules for remaining restricted stock units, with quarterly installments for the 41,853 RSU grant and the 58,300 RSU grant (starting June 1, 2025).

Industry Context

Form 4 filings are routine disclosures of insider transactions and do not typically provide industry-specific context. The transactions reflect standard equity compensation practices within publicly traded companies.

Comparison to Industry Standards

• The practice of granting performance stock units and restricted stock units, along with 'sell-to-cover' transactions for tax obligations, is a common and standard compensation practice for executives in the technology and healthcare industries. No specific comparable companies or projects are mentioned in the filing.

Stakeholder Impact

• Shareholders: A minor dilution effect from the vesting of new shares, offset by a small increase in shares available on the market from the tax-related sale. The overall impact on share price is likely negligible given the routine nature and small volume relative to total outstanding shares.

Next Steps

• Remaining restricted stock units from the March 3, 2023 grant will continue to vest in eight substantially equal quarterly installments.
• Remaining restricted stock units from the March 19, 2024 grant will vest one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. It does not provide new information regarding the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The transactions are standard practice and do not signal a significant shift in executive confidence or company prospects.

Keywords

Teladoc Health, TDOC, Insider Trading, Form 4, Executive Compensation, Stock Sale, Restricted Stock Units, Performance Stock Units, Equity Awards